Double maintains 1 strategies that include CGEM - Cullinan Therapeutics, Inc.
Yahoo
CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) wh
Yahoo
Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren’s disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025 Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a bioph
Finnhub
Cullinan Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 48.5 million compared to USD 37.15...
Yahoo
CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren’s disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no currently approved therapies CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the Company is
Yahoo
Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rateCAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that results from the REZILIENT1 study of zipalertinib in non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (ex20ins) who have received prior th
Yahoo
Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025 CLN-978 is also being studied in the U.S., Europe, and Australia for systemic lupus erythematosus CAMBRIDGE, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the European Medicines Agency (EMA) approved the C
Current Value
$7.871 Year Return
Current Value
$7.871 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IWC | 51.00% | $766.62M | 0.6% |
ARKG | 50.36% | $882.66M | 0.75% |
XBI | 50.25% | $4.66B | 0.35% |
GNOM | 49.51% | $40.78M | 0.5% |
CPRJ | 45.15% | $47.18M | 0.69% |
IWO | 44.89% | $11.06B | 0.24% |
IWM | 44.86% | $63.32B | 0.19% |
VTWO | 44.69% | $11.79B | 0.07% |
GSSC | 44.36% | $521.08M | 0.2% |
KJAN | 43.45% | $296.77M | 0.79% |
IBB | 43.33% | $5.22B | 0.45% |
KJUL | 43.33% | $112.85M | 0.79% |
IWN | 43.28% | $10.65B | 0.24% |
PBE | 43.26% | $218.51M | 0.58% |
SCHA | 42.77% | $16.45B | 0.04% |
KOMP | 42.64% | $2.14B | 0.2% |
PRFZ | 42.60% | $2.27B | 0.34% |
FYX | 42.39% | $787.16M | 0.6% |
ISCG | 42.13% | $645.31M | 0.06% |
DFAS | 41.96% | $9.66B | 0.27% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -13.70% | $24.22B | +29.30% | 1.06% |
T | -12.40% | $197.09B | +58.60% | 4.05% |
ED | -12.35% | $37.46B | +11.54% | 3.24% |
AWK | -11.36% | $27.91B | +13.39% | 2.19% |
AEP | -11.23% | $54.97B | +16.13% | 3.58% |
AMT | -10.93% | $100.04B | +15.49% | 3.10% |
VZ | -8.52% | $183.41B | +10.52% | 6.24% |
CME | -7.79% | $102.47B | +36.38% | 3.66% |
SO | -7.48% | $98.83B | +15.97% | 3.25% |
VSA | -7.37% | $6.80M | -46.67% | 0.00% |
MO | -7.01% | $100.43B | +31.09% | 6.78% |
CL | -6.71% | $74.91B | +0.53% | 2.17% |
KMB | -6.71% | $47.40B | +10.61% | 3.42% |
STG | -6.69% | $27.52M | -41.06% | 0.00% |
EXC | -6.00% | $44.33B | +19.39% | 3.57% |
DUK | -5.99% | $90.46B | +15.02% | 3.61% |
FE | -5.46% | $24.30B | +8.53% | 4.12% |
ES | -5.07% | $23.74B | +13.75% | 4.59% |
CCI | -4.92% | $43.79B | +2.92% | 6.26% |
TEF | -4.89% | $29.63B | +16.41% | 6.04% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BEAM | 49.45% | $1.71B | -29.69% | 0.00% |
DNLI | 47.17% | $1.92B | -30.11% | 0.00% |
CRBU | 45.53% | $101.38M | -63.55% | 0.00% |
IMNM | 44.98% | $748.31M | -41.18% | 0.00% |
FATE | 44.67% | $139.85M | -65.54% | 0.00% |
IDYA | 43.64% | $1.70B | -48.25% | 0.00% |
VRDN | 42.65% | $1.14B | +14.27% | 0.00% |
CRSP | 42.43% | $3.24B | -31.49% | 0.00% |
ABCL | 42.37% | $591.00M | -51.47% | 0.00% |
SYRE | 41.87% | $904.70M | -54.70% | 0.00% |
EYPT | 41.84% | $410.12M | -46.45% | 0.00% |
ATXS | 41.56% | $230.82M | -54.81% | 0.00% |
GBIO | 41.27% | $24.85M | -87.93% | 0.00% |
VYGR | 41.00% | $156.05M | -64.79% | 0.00% |
APGE | 40.54% | $2.20B | -22.94% | 0.00% |
COGT | 40.51% | $555.62M | -41.97% | 0.00% |
ADPT | 40.37% | $1.39B | +150.41% | 0.00% |
KFY | 40.26% | $3.55B | +3.14% | 2.32% |
NTLA | 40.23% | $965.91M | -58.96% | 0.00% |
QTRX | 39.80% | $197.45M | -69.22% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BSCR | 0.01% | $3.51B | 0.1% |
MMIT | -0.03% | $827.65M | 0.3% |
CANE | 0.09% | $10.92M | 0.29% |
JMST | -0.09% | $3.75B | 0.18% |
IUSB | -0.12% | $32.12B | 0.06% |
UCON | 0.12% | $2.99B | 0.85% |
MTBA | 0.14% | $1.43B | 0.17% |
HTAB | 0.17% | $405.03M | 0.39% |
FBND | 0.19% | $18.33B | 0.36% |
PYLD | -0.21% | $5.29B | 0.69% |
IBDR | 0.23% | $3.28B | 0.1% |
IBDQ | 0.27% | $3.06B | 0.1% |
SCMB | 0.32% | $1.96B | 0.03% |
SUB | -0.37% | $9.49B | 0.07% |
DBE | -0.39% | $48.03M | 0.77% |
GTO | 0.43% | $1.89B | 0.35% |
FLDR | 0.44% | $875.17M | 0.15% |
SLQD | 0.47% | $2.23B | 0.06% |
BLV | 0.52% | $6.00B | 0.03% |
FLMI | 0.53% | $666.64M | 0.3% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -32.89% | $327.18M | 1.43% |
VIXY | -29.12% | $132.94M | 0.85% |
TAIL | -27.99% | $118.28M | 0.59% |
FXY | -13.67% | $862.41M | 0.4% |
IBTG | -13.61% | $1.90B | 0.07% |
SPTS | -13.43% | $5.74B | 0.03% |
IVOL | -13.34% | $349.86M | 1.02% |
VGSH | -12.57% | $22.43B | 0.03% |
SCHO | -12.31% | $10.89B | 0.03% |
XONE | -11.96% | $610.77M | 0.03% |
IBTI | -11.90% | $1.01B | 0.07% |
AGZ | -11.46% | $607.85M | 0.2% |
UTWO | -11.29% | $384.85M | 0.15% |
IBTH | -11.25% | $1.54B | 0.07% |
SHY | -10.69% | $23.90B | 0.15% |
SCHR | -10.65% | $10.56B | 0.03% |
FTSD | -10.61% | $212.56M | 0.25% |
IBTM | -10.42% | $316.65M | 0.07% |
IBTJ | -10.17% | $667.91M | 0.07% |
IEI | -10.07% | $15.81B | 0.15% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LNG | 0.01% | $51.38B | +48.33% | 0.83% |
HRZN | -0.02% | - | - | 17.42% |
SBAC | -0.05% | $24.82B | +23.34% | 1.83% |
AQB | 0.05% | $3.37M | -52.72% | 0.00% |
LNT | -0.07% | $15.99B | +24.82% | 3.19% |
MKTX | 0.09% | $8.17B | +5.58% | 1.38% |
TU | 0.11% | $24.33B | -1.41% | 7.09% |
GIS | 0.13% | $29.64B | -18.82% | 4.44% |
VHC | 0.14% | $33.18M | +87.34% | 0.00% |
EVRG | -0.16% | $15.24B | +24.35% | 4.01% |
ABBV | 0.20% | $328.06B | +19.56% | 3.44% |
SRDX | 0.23% | $411.96M | -17.92% | 0.00% |
CQP | -0.25% | $28.38B | +18.78% | 5.57% |
BTI | 0.27% | $99.29B | +48.15% | 6.78% |
PPC | 0.29% | $11.46B | +51.06% | 0.00% |
VRSK | -0.31% | $44.23B | +27.04% | 0.51% |
NEE | 0.41% | $140.07B | -12.24% | 3.12% |
STZ | 0.57% | $33.09B | -24.27% | 2.19% |
KR | -0.59% | $45.16B | +29.67% | 1.89% |
SBRA | -0.65% | $4.19B | +23.34% | 6.90% |